SynthesisPediatric nephrology (Berlin, Germany)2025
Utilization of the modified Bosniak classification system for complex renal cysts.
Synthesis in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolid renal masses are commonly managed through surgical intervention, while conservative management is the preferred approach for simple renal cysts. However, the optimal management strategies for complex renal cysts in children remain unresolved.
objectiveTo conduct a meta-analysis of the literature on the modified Bosniak (mBosniak) classification system to assess its diagnostic performance in pediatric complex renal cysts. DATA SOURCES AND STUDY ELIGIBILITY CRITERIA: A predefined database search (January 1986-December 2023), used the following keywords: Bosniak classification, modified Bosniak, pediatric renal cysts, complex renal cyst, and pediatric renal tumor. Two independent reviewers extracted data on mBosniak categories and their associated pathology diagnoses. The inclusion criteria comprised (1) English-language publications, (2) involving the pediatric population, (3) using the mBosniak classification and (4) incorporating histopathological data. STUDY APPRAISAL AND SYNTHESIS
methodsThe quality of studies was assessed using the QUADAS-2 tool. The analysis involved pooling data, performing subgroup analyses, and exploring potential publication bias.
resultsA total of 7 retrospective studies, which included 154 lesions and 368 scan readings, were included. The overall prevalence of intermediate/malignant lesions was 70% (257/368). In distinguishing benign from intermediate/malignant pathology using the mBosniak classification (I-II vs. III-IV), the overall pooled sensitivity, specificity, PPV, and NPV were 0.88 (227/257), 0.74 (82/111), 0.89 (227/256), and 0.73 (82/112), respectively. mBosniak III category showed a PPV of 0.78 (70/90) and mBosniak II category showed a NPV of 0.59 (36/61). From the perspective of pathological diagnoses, 0.24 (29/122) of the readings for intermediate-risk lesions inaccurately categorized the lesions as mBosniak I-II. The diagnostic performance of the classification varies among distinct subgroups of patients and lesion characteristics. LIMITATIONS: We included studies with pathologically verified lesions only. In addition, aspects of the radiographic follow-up, such as the duration of follow-up, changes in cyst complexity or size over time, and the correlation between specific dynamics and malignancy, could not be evaluated based on the data provided in the included studies. CONCLUSIONS AND IMPLICATIONS OF KEY
findingsThe mBosniak classification is a less precise tool for stratifying the challenging cases of intermediate-risk lesions, and the relatively low predictive values of the middle categories (II-III) cast doubt on its utility. Clinicians should incorporate additional clinical-epidemiological data for a more accurate assessment of these lesions. Registration number CRD42023493223.
Indexed as
Identifiers
40504241What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.